共 50 条
- [41] Preliminary Results of a Phase II Trial of Panobinostat (LBH589) In Refractory Myelodysplastic Syndromes (MDS) PatientsBLOOD, 2010, 116 (21) : 1636 - 1637Flinn, Ian W.Lang, EvanRaefsky, EricBoccia, RalphMacias-Perez, Ines M.Burris, Howard A., IIIHainsworth, John D.
- [42] Pharmacokinetic (PK) and pharmacodynamics (PD), study of two doses of bortezomib (Btz) in patients with relapsed multiple myeloma (MM).BLOOD, 2006, 108 (11) : 1008A - 1008AStewart, A. KeithSullivan, DanLonial, SagarMohrbacher, Ann F.Chatta, GurkamalShustik, ChaimBurris, Howard, IIIKarol, MichaelZannikos, PeferReece, Donna E.
- [43] Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myelomaCANCER MEDICINE, 2023, 12 (04): : 3999 - 4009Victoria Mateos, MariaProsper, FelipeMartin Sanchez, JesusOcio, Enrique M.Oriol, AlbertMotllo, CristinaMichot, Jean-MarieJarque, IsidroIglesias, RebecaSole, MariaMartinez, SaraKahatt, CarmenFudio, SalvadorCorral, GemaZeaiter, AliMontilla, LolaRibrag, Vincent
- [44] Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple MyelomaBLOOD, 2014, 124 (21)Richardson, Paul G.Hungria, Vania T. M.Yoon, Sung-SooBeksac, MeralDimopoulos, Meletios A.Elghandour, AshrafJedrzejczak, Wieslaw WiktorGuenther, AndreasThanyaphong Na NakornSiritanaratkul, NoppadolSchlossman, Robert L.Hou, JianMoreau, PhilippeLonial, SagarLee, Jae HoonEinsele, HermannSalwender, HansSopala, MonikaPanneerselvam, AshokRedhu, SumanCorrado, ClaudiaBinlich, FlorenceSan Miguel, Jesus F.
- [45] Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myelomaHAEMATOLOGICA, 2015, 100 (05) : 670 - 676Berdeja, Jesus G.Hart, Lowell L.Mace, Joseph R.Arrowsmith, Edward R.Essell, James H.Owera, Rami S.Hainsworth, John D.Flinn, Ian W.
- [46] A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM).JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Berdeja, Jesus G.Gregory, Tara K.Matous, JeffreyHart, Lowell L.Owera, RamiMace, Joseph RonaldEssell, James H.Flinn, IanFaber, Edward Anthony
- [47] Phase II trial of panobinostat (LBH589) in patients (pts) with refractory metastatic colorectal cancer (MCRC).JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)Gold, Philip JordanSmith, David A.Iriarte, DesireeBoatman, BarryKaplan, Henry G.
- [48] A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Yee, Andrew JenhoLaubach, JacobCampagnaro, Erica LeighLipe, BreaNadeem, OmarCole, CraigO'Donnell, ElizabethSchlossman, Robert L.Bianchi, GiadaBranagan, Andrew RobertShapiro, Samantha J.Harrington, Cynthia C.Burke, Jill N.Gammon, Marilyn T.Lively, Kathleen J.Thorburn, Cassandra AnnMann, Mason L.Lohr, Jens GuenterRichardson, Paul G.Raje, Noopur S.
- [49] Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin LymphomaBLOOD, 2010, 116 (21) : 1617 - 1617Younes, AnasCopeland, AmandaFanale, Michelle A.Hagemeister, FredrickFayad, LuisPro, BarbaraFaria, Silvana C.Ji, YuanMedeiros, L. JeffreyBerry, Donald A.Buglio, Daniela
- [50] A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and IV Bortezomib in Patients with Relapsed Multiple Myeloma.BLOOD, 2009, 114 (22) : 1481 - 1482San-Miguel, Jesus F.Sezer, OrhanSiegel, DavidGuenther, AndreasMateos, Maria-VictoriaProsser, IanCavo, MicheleBlade, JoanBoccadoro, MarioBengoudifa, Bourras R.Klebsattel, MartinBourquelot, Priscille M.Anderson, Kenneth C.